» Articles » PMID: 35204804

Tumor Suppressor Role of Wild-Type P53-Dependent Secretome and Its Proteomic Identification in PDAC

Abstract

The study of the cancer secretome is gaining even more importance in cancers such as pancreatic ductal adenocarcinoma (PDAC), whose lack of recognizable symptoms and early detection assays make this type of cancer highly lethal. The wild-type p53 protein, frequently mutated in PDAC, prevents tumorigenesis by regulating a plethora of signaling pathways. The importance of the p53 tumor suppressive activity is not only primarily involved within cells to limit tumor cell proliferation but also in the extracellular space. Thus, loss of p53 has a profound impact on the secretome composition of cancer cells and marks the transition to invasiveness. Here, we demonstrate the tumor suppressive role of wild-type p53 on cancer cell secretome, showing the anti-proliferative, apoptotic and chemosensitivity effects of wild-type p53 driven conditioned medium. By using high-resolution SWATH-MS technology, we characterized the secretomes of p53-deficient and p53-expressing PDAC cells. We found a great number of secreted proteins that have known roles in cancer-related processes, 30 of which showed enhanced and 17 reduced secretion in response to p53 silencing. These results are important to advance our understanding on the link between wt-p53 and cancer microenvironment. In conclusion, this approach may detect a secreted signature specifically driven by wild-type p53 in PDAC.

Citing Articles

Nutri-PEITC Jelly Significantly Improves Progression-Free Survival and Quality of Life in Patients with Advanced Oral and Oropharyngeal Cancer: A Blinded Randomized Placebo-Controlled Trial.

Lam-Ubol A, Sukhaboon J, Rasio W, Tupwongse P, Tangshewinsirikul T, Trachootham D Int J Mol Sci. 2023; 24(9).

PMID: 37175527 PMC: 10177844. DOI: 10.3390/ijms24097824.


p53 Function and Dysfunction in Human Health and Diseases.

DOrazi G Biomolecules. 2023; 13(3).

PMID: 36979441 PMC: 10046821. DOI: 10.3390/biom13030506.


Oncogenic KRAS-Induced Protein Signature in the Tumor Secretome Identifies Laminin-C2 and Pentraxin-3 as Useful Biomarkers for the Early Diagnosis of Pancreatic Cancer.

Kamal M, Siddiqui I, Belgiovine C, Barbagallo M, Paleari V, Pistillo D Cancers (Basel). 2022; 14(11).

PMID: 35681634 PMC: 9179463. DOI: 10.3390/cancers14112653.

References
1.
Kruiswijk F, Labuschagne C, Vousden K . p53 in survival, death and metabolic health: a lifeguard with a licence to kill. Nat Rev Mol Cell Biol. 2015; 16(7):393-405. DOI: 10.1038/nrm4007. View

2.
Baum B, Georgiou M . Dynamics of adherens junctions in epithelial establishment, maintenance, and remodeling. J Cell Biol. 2011; 192(6):907-17. PMC: 3063136. DOI: 10.1083/jcb.201009141. View

3.
Blandino G, Levine A, Oren M . Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene. 1999; 18(2):477-85. DOI: 10.1038/sj.onc.1202314. View

4.
Wu Y, Lee Y, Li W, Hsu W, Lin H, Chang L . High Transaldolase 1 expression predicts poor survival of patients with upper tract urothelial carcinoma. Pathol Int. 2021; 71(7):463-470. DOI: 10.1111/pin.13101. View

5.
Baker S, Markowitz S, Fearon E, WILLSON J, Vogelstein B . Suppression of human colorectal carcinoma cell growth by wild-type p53. Science. 1990; 249(4971):912-5. DOI: 10.1126/science.2144057. View